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Background: The absence of defined goals of therapy in patients admitted with acutely decompensated heart failure (ADHF) is associated with 
significant short and long-term morbidity and mortality. The Seattle Heart Failure Model (SHFM), a multivariate risk model that predicts 1-, 2-, and 
3-year survival in chronic stable heart failure patients using characteristics related to clinical status, therapy and laboratory parameters, accurately 
predicts survival in outpatients with heart failure. 
Methods: Using data retrospectively obtained from 202 consecutive patients admitted with a primary diagnosis of AHDF, we tested the hypothesis 
that in-patient optimization of the SHFM can provide therapeutic goals to enhance survival in this patient population. 
Results: Optimization according to mean life expectancy by quartiles (5.9, 8.3, 11.0 and 14.1 years) simultaneously resulted in a reduction in 
mean length of stay (10.9, 9.0, 7.4 and 6.1 days, respectively; each quartile p <0.001). Post SHFM optimization was associated with an increase in 
1 year (84.0 vs 98.5%, p < 0.01), 2 year (79.8 vs 95.4%, p < 0.01) and 5 year (46.3 vs 86.3%, p < 0.01) survival (from lowest to highest quartiles). 
Reduction in the use of metolazone, at the expense of increased loop diuretic usage, and increased beta blocker and mineralocorticoid inhibitor 
usage were each associated with enhanced long-term survival and decreased length of stay. No significant differences were noted regardless of 
gender, age, etiology of heart failure or baseline LVEF. In-hospital optimization of the SHFM was also associated with a significant improvement in 
NYHA class and a lowering of serum BUN (but not creatinine) at discharge (p < 0.5 for each quartile). 
Conclusion: These data suggest that in patients admitted with ADHF, novel optimization of a patient’s clinical profile by utilization of an idealized 
Seattle Heart Failure score may result in improved long term survival and reduction in mean length of stay.
